Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

@article{Wells2015AfliberceptBO,
  title={Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.},
  author={John A Wells and Adam R. Glassman and Allison R. Ayala and Lee M. Jampol and Lloyd Paul Aiello and Andrew N. Antoszyk and Bambi Arnold-Bush and Carl W Baker and Neil M. Bressler and David J Browning and Michael J Elman and Frederick L. Ferris and Scott M Friedman and Mart{\'i} Mestre Meli{\'a} and Dante Joseph Pieramici and Jennifer K. Sun and Roy W Beck},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 13},
  pages={1193-203}
}
BACKGROUND The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown. METHODS At 89 clinical sites, we randomly assigned 660 adults (mean age, 61±10 years) with diabetic macular edema involving the macular center to receive intravitreous aflibercept at a dose of 2.0 mg (224 participants), bevacizumab at a dose of 1.25 mg (218 participants), or ranibizumab at a dose of 0.3 mg (218 participants). The study… CONTINUE READING
Highly Influential
This paper has highly influenced 14 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 208 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Diabetic Retinopathy

Network, JA Wells, AR Glassman, AR Ayala
N Engl J Med • 2015
View 5 Excerpts
Highly Influenced

A fl ibercept , bevacizumab , or ranibizumab for diabetic macular edema

JA Wells, AR Glassman, AR Ayala
N Engl J Med • 2015

Intravitreal a fl i - bercept for diabetic macular edema : 100 - week results from the VISTAandVIVID studies

QD Nguyen, DM Brown, DM Marcus
Ophthalmology • 2015

Similar Papers

Loading similar papers…